Skip Navigation



NDT Advance Access published online on November 5, 2008
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfn601
This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
24/4/1082    most recent
gfn601v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Vaziri, N. D.
Right arrow Articles by Zhou, X. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vaziri, N. D.
Right arrow Articles by Zhou, X. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease

Nosratola D. Vaziri1 and Xin J. Zhou2

1 Division of Nephrology and Hypertension, Department of Medicine, Physiology and Biophysics, University of California, Irvine, CA 2 Department of Pathology, UT Southwestern Medical Center, Dallas, TX, USA

Correspondence and offprint requests to: Nosratola D. Vaziri, Division of Nephrology and Hypertension, UCI Medical Center, 101 The City Drive, Bldg 53 Rm 125 Rt 81, Orange, CA 92868, USA. Tel: +1-714-456-5142; Fax: +1-714-456-6034; E-mail: ndvaziri{at}uci.edu

Keywords: anemia; cardiovascular disease; erythropoietin; progression of CKD; vascular access thrombosis



   Introduction
Top
 Introduction
Conclusions
 References
 
Advanced chronic kidney disease (CKD, stages 3–5) is almost invariably associated with anemia that is primarily caused by depressed production of erythropoietin (EPO), oxidative stress and inflammation [1,2]. This can be compounded by iron deficiency that is caused by loss of blood from repetitive laboratory tests, residual blood remaining in the hemodialysis circuits, fistula puncture site bleeding and uremic platelet dysfunction. In addition, when present, hemolytic disorders, bone marrow suppression, nutritional deficiencies, drug toxicities and hereditary diseases exacerbate the CKD-associated anemia.

The EPO-deficiency and iron-deficiency components of anemia are routinely corrected with the use of recombinant human EPO and iron preparations. However, presence of severe oxidative stress and inflammation hampers efficacy of EPO and iron in promoting erythropoiesis. In this context, severe persistent anemia despite high doses of EPO and iron is commonly due to oxidative stress and inflammation that may actually be intensified by intravenous iron and EPO administration [3–5]. Observational studies have revealed a strong association between severity of anemia and risk of morbidity and mortality from cardiovascular disease and other causes in CKD patients [6–10]. These findings have been widely interpreted as evidence for the causal role of anemia in the pathogenesis of adverse outcomes in this population. Contrary to expectations, randomized clinical trials of anemia correction revealed either no effect or increased morbidity and mortality in patients assigned to normal hemoglobin (Hb) targets [11–13]. In fact, meta-analyses of randomized clinical trials have shown a significant increase in cardiovascular and all-cause mortality and arteriovenous access thrombosis among patients assigned to the higher than those randomized to the lower Hb targets [14–15]. These findings have been generally considered to imply that complete correction of anemia might have caused the adverse outcomes. Based on this assumption, K/DOQI guidelines were recently revised by reducing the optimum target Hb to 11–12 g/dl [16].

This article is intended to explore the reasons for the apparent contradiction between the results of observational and randomized clinical trials of anemia treatment in the CKD population. To address these issues, we have utilized relevant data derived from basic and translational studies.

Analysis of the link between anemia and adverse outcomes
As noted above, the positive correlation between severity of anemia and adverse outcomes has been widely taken to imply that adverse outcomes are caused by anemia in CKD populations. It is of note that anemia in dialysis-dependent CKD patients is generally treated with EPO and iron preparations. Consequently, when present, severe persistent anemia in this population is primarily due to EPO resistance as opposed to the lack of treatment. A frequent cause of the poorly responsive anemia in CKD patients is inflammation that is a common feature of advanced renal insufficiency [17,18] and can simultaneously cause anemia, cardiovascular disease and other disorders (Figure 1). The chronic renal failure (CRF)-induced oxidative stress and inflammation is frequently intensified by comorbid conditions such as diabetes, hypertension, autoimmune disorders and systemic and local infections (e.g. hepatitis, infected hemodialysis blood access and peritoneal catheters).


Figure 1
View larger version (34K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 1 Figure illustrating the interconnection of oxidative stress and inflammation and their ability to simultaneously cause cardiovascular disease and EPO-resistant anemia. Abbreviations: RES, reticuloendothelial system; GI, gastrointestinal tract; RBC, red blood cell; Rx, treatment.

 
Oxidative stress and inflammation are inseparably interconnected and when present raise the risk of morbidity and mortality from cardiovascular disease and other causes by promoting endothelial dysfunction, hypertension, atherosclerosis and numerous other disorders. For instance, oxidative stress and inflammation drive atherosclerosis by promoting oxidation of lipids/lipoproteins, activation of endothelial cells, adhesion, infiltration and transformation of monocyte to foam cells, migration, proliferation and phenotypic transformation of vascular smooth muscle cells, plaque formation, plaque rupture, release of matrix metalloproteinases and tissue factor and eventual thrombosis [19,20]. In addition, oxidative stress and inflammation impair HDL-mediated reverse cholesterol transport and reduce the anti-inflammatory and anti-oxidant properties of HDL [21]. Simultaneously, oxidative stress and inflammation cause EPO-resistant anemia [1,2,22] by the following mechanisms: (i) oxidation of erythrocyte membrane phospholipids and depletion of redox capacity leading to a shortened erythrocyte life span, (ii) hepatic production of hepcidin which by binding to ferroportin blocks intestinal absorption and mobilization of stored iron [22], (iii) reduction of transferrin production and hence diminished iron availability and finally, (iv) resistance to erythropoietic action of EPO.

Therefore, in the presence of inflammation, a strong correlation between anemia and cardiovascular disease primarily reflects their surrogacy as opposed to a causal relationship. It should be noted however that by increasing cardiac output, severe anemia can cause left ventricular dilation and heart failure and aggravate symptoms of pre-existing coronary artery disease.

Anemia correction versus drug toxicity as the cause of adverse outcomes
The observational studies implying a link between severity of anemia and adverse outcomes prompted a number of randomized clinical trials testing the hypothesis that correction of anemia may improve cardiovascular outcomes [11–13]. Contrary to the expectation, patients randomized to normal Hb groups showed either no benefit or increased adverse cardiovascular and other outcomes. These findings were taken to imply that correction of anemia can be harmful in CKD patients. It is of note that despite large doses of EPO and iron, only a minority of patients assigned to the high-Hb groups reached the expected target (21% in CHOIR and 38% in CREATE) [12,13]. This indicates that a large segment of populations enrolled in these studies had severe treatment-resistant anemia most likely due to significant oxidative stress and inflammation. In addition to their erythropoietic actions, EPO and iron have many other effects that are beneficial at physiological and hazardous at high levels. Consequently, increased morbidity and mortality in patients randomized to the higher Hb targets in clinical trials could be due to EPO and possibly iron overdose as opposed to anemia correction which was not even achieved in the majority of patients. This assertion is supported by the observation that a subgroup of patients whose Hb could be normalized did considerably better [11] and that CKD patients (e.g. polycystic kidney disease) who maintain normal Hb without EPO therapy usually do as well as or better than their anemic counterparts [23]. It is of note that in the randomized clinical trials of anemia correction, the median dose of EPO administered to patients assigned to the normal or near-normal Hb groups was two-threefolds greater than that used in those assigned to the lower Hb groups [11–13]. Moreover, secondary analysis of data in the CHOIR study revealed that the inability to achieve a target Hb and high EPO dose were each significantly associated with an increased risk of the primary endpoints, i.e. death, myocardial infarction, congestive heart failure or stroke [24]. Taken together, these observations point to a possible role of non-erythropoietic actions of high doses of EPO (and possibly iron) that are briefly described here.

Non-erythropoietic effects of EPO
EPO receptors are widely expressed in many non-erythropoietic cells and tissues including endothelial cells, vascular smooth muscle cells, cardiomyocytes, skeletal myoblasts, neurons, liver stromal cells, macrophages, kidney, retina, placenta and a variety of cancer cells. Activation of these receptors by EPO can account for its numerous non- erythropoietic effects including angiogenic, anti-apoptotic, vaso-regulatory, hemostatic and other actions that are highly advantageous at physiological and potentially harmful at high EPO levels/doses. Some of the positive and negative EPO actions affecting the cardiovascular system, blood coagulation and kidney are briefly described here and summarized in Figure 2.


Figure 2
View larger version (36K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 2 Figure illustrating the non-erythropoietic actions of EPO that can potentially contribute to the development of hypertension, hemodialysis blood access stenosis, diabetic proliferative retinopathy, vascular remodeling, thrombosis and tumor growth. Abbreviations: VSMC, vascular smooth muscle cell; RAS, rennin angiotensin system; EC, endothelial cells; ADMA, asymmetrical dimethylarginine; NO, nitric oxide; vWF, von Willibrand factor; PAI-1, plasminogen activator inhibitor.

 
Effect of EPO on arterial pressure.
EPO administration causes hypertension in CKD patients and experimental animals [25,26]. The EPO-induced hypertension is unrelated to its erythropoietic action since it occurs in both iron-deficient and iron-sufficient CKD animals despite persistent anemia in the former [27,28]. Moreover, anemia correction with multiple red cell transfusions in CKD animals or iron repletion in iron-deficient CKD patients does not raise arterial pressure [27–29]. These observations provide irrefutable evidence that EPO-induced hypertension is not mediated by changes in erythrocyte mass and instead is caused by the drug itself. The mechanisms of action of EPO on arterial pressure and the cardiovascular system have been reviewed in detail elsewhere [25,26] and are briefly outlined here:
  1. Cytosolic ionized calcium concentration ([Ca2+]i)— EPO raises cytosolic [Ca2+]i and expands sarcoplasmic calcium stores [27,28,30], in vascular smooth muscle cells (VSMC). These events, in turn, reduce vasodilator response to nitric oxide (NO) and raise systemic vascular resistance and arterial pressure.
  2. Endothelin-1 (ET-1)—EPO therapy raises plasma ET-1 in dialysis patients [31], increases ET-1 production in isolated vessels and cultured endothelial cells [31–33]. Increased ET-1 production can, in turn, promote vasoconstriction, ROS generation and hypertension.
  3. Renin angiotensin system (RAS)—EPO increases renin and angiotensinogen mRNA in the rat kidney and vasculature [34], up-regulates renin, angiotensinogen and angiotensin receptor expression in cultured VSMC and heightens the expression of several angiotensin II-responsive factors including TGF-beta, insulin-like growth factor-II, epidermal growth factor, c-fos and platelet-derived growth factor [35]. Interestingly, homozygosity for T allele of angiotensinogen gene is associated with EPO-induced hypertension in CKD patients [36]. Finally, EPO therapy accelerates progression of renal disease in five of six nephrectomized rats that respond favorably to AT1 receptor blockade and ACE inhibition [37].
  4. Prostaglandins—EPO increases PGF2 {alpha} and thromboxane and lowers prostacyclin release in cultured human endothelial cells [33] and in the vascular tissue of CKD rats [38,39].

Thus, by raising VSMC [Ca2+]i, activating tissue RAS, increasing endothelin-1 production and elevating thromboxane/prostacyclin ratio in the vascular tissue, long-term administration of high doses of EPO can promote hypertension and vascular injury. On the other hand, by increasing vascular tone, EPO therapy lowers susceptibility to intra-dialytic hypotension in end-stage renal disease (ESRD) patients. This can, in turn, facilitate management of hypervolemia by ultrafiltration during hemodialysis.

Effect of EPO on vascular cell growth.
EPO dose-dependently stimulates endothelial [40] and VSMC proliferation [41,42], promotes angiogenesis [43], facilitates mobilization of endothelial progenitor cells and up-regulates vascular endothelial growth factor expression [44]. EPO promotes survival and hinders apoptosis in endothelial cells, renal tubular epithelial cells, cardiomyocytes and nerve cells subjected to ischemia–reperfusion or toxic injury [45–47]. These attributes of EPO are potentially protective against acute injury. However, the angiogenic and anti-apoptotic properties of EPO particularly at high doses may accelerate tumor growth in patients with cancer, accelerate proliferative retinopathy in diabetics [48] and cause allograft renal artery stenosis in transplant recipients [49]. Moreover, via activation of NFkB and production of growth factors, cytokines and pro-fibrotic mediators, high doses of EPO may stimulate tissue remodeling and inflammation [35,50,51].

Effects of EPO on the platelet and coagulation system.
EPO administration significantly increases platelet count (independently of its effect on hematocrit) in ESRD patients with platelet counts <150 000/mm3 [52]. This phenomenon is due to amplification of the thrombopoietic action of thrombopoietin by EPO. In addition, by increasing intracellular calcium stores and intensifying the surge in cytosolic [Ca2+]i following activation [53], EPO enhances platelet reactivity that can cause a pro-thrombotic state. Moreover, EPO can enhance blood coagulation by stimulating production of E selectin, P selectin, von Willebrand factor (vWF) and plasminogen activator inhibitor-1 and by activating pathways involved in tissue factor expression [54–57].

Thus, while the ability of EPO to reverse uremic platelet dysfunction is beneficial, high doses of EPO can cause thrombotic complications as reported in CKD and oncology patients [14,58].

Effect of EPO on the nitric oxide pathway.
Asymmetrical dimethylarginine (ADMA) is a potent endogenous inhibitor of NO synthase. Elevation of ADMA is associated with endothelial dysfunction, oxidative stress and atherosclerosis. ADMA is degraded by the enzyme, dimethylarginine dimethylaminohydrolase (DDAH). EPO dose-dependently raises ADMA level via down-regulation of DDAH, lowers NO production, increases ROS generation [59] and down-regulates NO synthase expression [60] in cultured endothelial cells.

Thus, at high doses, EPO can potentially limit endothelium-derived NO production that can, in turn, contribute to endothelial dysfunction, hypertension, cardiovascular remodeling and thrombosis.

Effect of EPO on the heart.
Left ventricular hypertrophy (LVH), ischemic heart disease and congestive heart failure (CHF) are highly prevalent among CKD patients. Population studies have found strong correlations between severity of anemia and prevalence of LVH and CHF in this population [61–63]. These cardiac abnormalities have been, in part, attributed to the reduction of oxygen delivery, increased cardiac output and heightened sympathetic activity occasioned by severe anemia. Several uncontrolled studies suggested that partial correction of anemia with EPO therapy may result in prevention or regression of CHF [64,65] and LVH [66–68]. However, large controlled randomized clinical trials have shown no improvement in either LVH or CHF with anemia correction in either dialysis-dependent or as yet dialysis-independent CKD patients [11,12,69–72]. It is of note that EPO has been shown to reduce the extent of apoptosis of cardiomyocytes, severity of infarct and subsequent left ventricular dilation and dysfunction following ischemia–reperfusion injury in experimental animals [73–77]. These beneficial effects are related to the direct anti-apoptotic action of EPO and are unrelated to anemia correction and as such may not be extended to chronic heart disease. Moreover, via its pro-thrombotic actions, EPO may extend coronary thrombosis and as such may be deleterious in acute myocardial infarction.

Effect of EPO on the kidney.
Both vascular and non-vascular components of the kidney express functional EPO receptors [78]. Activation of the EPO receptor deters apoptosis and enhances cell survival. Several studies have shown that EPO administration can reduce apoptotic cell death and enhance recovery of kidney function and structure in various models of acute kidney injury induced by ischemia–reperfusion or nephrotoxic agents [47,79–81]. Similarly, EPO has been shown to exert anti-apoptotic action in cultured podocytes in vitro [82].

The favorable effect of EPO in promoting cell survival in models of acute injury is countered by its ability to increase platelet production, augment platelet reactivity and up-regulate endothelial cell expression of tissue factor and other pro-thrombotic molecules described earlier. The latter events can intensify injury and impede recovery by facilitating microvascular thrombosis as well as the release of pro-fibrotic, pro-inflammatory mediators from activated platelets and coagulation proteins such as thrombin. This scenario is particularly likely when parenchymal injury is accompanied by endothelial damage and dysfunction that is commonly present in many forms of acute and chronic kidney disease, hypertension and cardiovascular disorders, among others.

It has been speculated that the inherent limitation of oxygen delivery in the anemic state can accelerate apoptotic cell death and promote fibrosis and hence, contribute to progression of chronic diseases of the kidney or other organs. If true, correction of anemia should confer benefit by retarding progression of the disease. Interestingly, a few studies have shown that administration of low sub-erythropoietic doses of EPO may retard progression of renal disease in rats with renal mass reduction [83] and in diabetic db/db mice [84]. Similarly, partial amelioration of anemia with low doses of EPO was reported to slow the rate of progression to ESRD in a group of CKD patients [85]. In contrast, high doses of EPO have been consistently shown to accelerate progression of renal disease in animals with renal mass reduction [37,83,86], diabetes [84] and anti-basement membrane antibody-induced glomerulonephritis [82]. Similarly, recent large randomized clinical trials revealed a significant trend for progression to ESRD necessitating renal replacement therapy among patients assigned to the high-Hb groups [12,13]. The contribution of high levels of EPO to progression of renal disease is enforced by the recent demonstration of a strong link between development of severe diabetic proliferative retinopathy and nephropathy with a polymorphism of the EPO gene promoter that causes increased EPO production [87].

Thus, while physiologic levels of EPO confer vital benefits through its numerous non-erythropoietic and erythropoietic actions, data derived from experimental animals and randomized clinical trials suggest that high doses of EPO can accelerate progression of chronic renal disease. These effects are most likely related to the pleotropic actions of EPO amplified by pre-existing inflammation and endothelial dysfunction.

Potential contribution of non-erythropoietic actions of EPO to adverse outcomes
The unintended effects of high doses of EPO that were briefly noted above can contribute to the adverse outcomes seen in clinical trials of anemia correction in CKD populations. It is of note that resistance to erythropoietic actions of EPO is not necessarily accompanied by resistance to its non-erythropoietic effects. This is clearly exemplified by the ability of recombinant EPO to cause an equally severe hypertension and to amplify calcium signaling in iron-deficient and iron-sufficient CKD rats despite persistent anemia in the former and its corrections in the latter [26,27]. Thus, dose escalation of EPO can lead to adverse outcomes emanating from its non-erythropoietic effects in patients with EPO-resistant anemia. It is of note that CDK results in marked shortening of the erythrocyte lifespan that is not affected by the currently available therapeutic tools. Consequently, maintenance of normal erythrocyte mass in patients with advanced CKD, particularly when accompanied by severe oxidative stress and inflammation, demands high levels of sustained erythropoiesis that are far greater than that required in normal individuals. Therefore, aggressive interventions to maintain normal or near-normal erythrocyte mass in such individuals often requires high doses of EPO that can lead to drug overdose and toxicity.



   Conclusions
Top
 Introduction
 Conclusions
References
 
We believe that contrary to common perceptions, association of severity of anemia with adverse outcomes shown in observational studies represents surrogacy as opposed to causal relationship. Instead, the real culprits are oxidative stress, inflammation and diminished biological capacity that simultaneously cause treatment-resistant anemia and adverse cardiovascular and other outcomes. Similarly, we believe that increased morbidity and mortality observed in randomized clinical trials of anemia correction most likely represent drug overdose/toxicity as opposed to normalization of Hb. Consequently, in our opinion caution should be exercised when escalating the EPO dosage in an attempt to achieve the desired Hb level in EPO-resistant patients.

Conflict of interest statement. None declared.



   References
Top
 Introduction
 Conclusions
 References
 

  1. Besarab A. Anemia of renal disease in diseases of kidney and urinary tract. In: Diseases of the Kidney and Urinary Tract—Schrier RW, ed. (2001) 7th edn. Philadelphia, PA: Lippincott, Williams and Company. 2719–2734.
  2. Locatelli F, Andrulli S, Memoli B, et al. Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients. Nephrol Dial Transplant (2006) 2:991–998.
  3. Herrera J, Nava M, Romero F, et al. Melatonin prevents oxidative stress resulting from iron and erythropoietin administration. Am J Kidney Dis (2001) 37:750–757.[Web of Science][Medline]
  4. Lim CS, Vaziri ND. The effects of iron dextran on the oxidative stress in cardiovascular tissues of rats with chronic renal failure. Kidney Int (2004) 65:1802–1809.[CrossRef][Web of Science][Medline]
  5. Lim PS, Wei YH, Yu YL, et al. Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant (1999) 14:2680–2687.[Abstract/Free Full Text]
  6. Collins AJ, Li S, St Peter W, et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol (2001) 12:2465–2473.[Abstract/Free Full Text]
  7. Li S, Collins AJ. Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients. Kidney Int (2004) 65:626–633.[CrossRef][Web of Science][Medline]
  8. Robinson BM, Joffe MM, Berns J, et al. Anemia and mortality in hemodialysis patients: accounting for morbidity and treatment variables updated over time. Kidney Int (2005) 68:2323–2330.[CrossRef][Web of Science][Medline]
  9. Locatelli F, Pisoni RL, Combe C, et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant (2004) 19:121–132.[Abstract/Free Full Text]
  10. Wolfe RA, Hulbert-Shearon TE, Ashby VB, et al. Improvements in dialysis patient mortality are associated with improvements in urea reduction ratio and hematocrit, 1999 to 2002. Am J Kidney Dis (2005) 45:127–135.[CrossRef][Medline]
  11. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med (1998) 339:584–590.[Abstract/Free Full Text]
  12. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med (2006) 355:2071–2084.[Abstract/Free Full Text]
  13. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med (2006) 355:2085–2098.[Abstract/Free Full Text]
  14. Phrommintikul A, Haas SJ, Elsik M, et al. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet (2007) 369:381–388.[CrossRef][Web of Science][Medline]
  15. Parfrey PS. Target hemoglobin level for EPO therapy in CKD. Am J Kidney Dis (2006) 47:171–173.[CrossRef][Web of Science][Medline]
  16. NKF-K/DOQI. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis (2007) 50:474.
  17. Himmelfarb J, Stenvinkel P, Ikizler TA, et al. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int (2002) 62:1524–1538.[CrossRef][Web of Science][Medline]
  18. Vaziri ND. Oxidative stress in uremia. Nature, mechanisms and potential consequences. Semin Nephrol (2004) 24:469–473.[Web of Science][Medline]
  19. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med (2005) 352:1685–1695.[Free Full Text]
  20. Aikawa M, Libby P. The vulnerable atherosclerotic plaque: pathogenesis and therapeutic approach. Cardiovasc Pathol (2004) 13:125–138.[Web of Science][Medline]
  21. Ansell BJ, Fonarow GC, Fogelman AM. The paradox of dysfunctional high-density lipoprotein. Curr Opin Lipidol (2007) 18:427–434.[CrossRef][Web of Science][Medline]
  22. Ganz T. Molecular control of iron transport. J Am Soc Nephrol (2007) 18:394–400.[Abstract/Free Full Text]
  23. Kuo CC, Lee CT, Chuang CH, et al. Recombinant human erythropoietin independence in chronic hemodialysis patients: clinical features, iron homeostasis and erythropoiesis. Clin Nephrol (2005) 63:92–97.[Web of Science][Medline]
  24. Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int (2008).
  25. Vaziri ND. Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis (1999) 33:821–828.[Web of Science][Medline]
  26. Vaziri ND. Cardiovascular effects of erythropoietin and anemia correction. Curr Opin Nephrol Hypertens (2001) 10:633–637.[CrossRef][Web of Science][Medline]
  27. Vaziri ND, Zhou XJ, Naqvi F, et al. Role of nitric oxide resistance in erythropoietin-induced hypertension in rats with chronic renal failure. Am J Physiol (Endocrinol Metab) (1996) 271:E113–E122.[Abstract/Free Full Text]
  28. Vaziri ND, Zhou XJ, Smith J, et al. In vivo and in vitro pressor effects of erythropoietin in rats. Am J Physiol (Renal Fluid Electrolyte Physiol) (1995) 269:F838–F845.[Abstract/Free Full Text]
  29. Kaupke CJ, Kim S, Vaziri ND. Effect of erythrocyte mass on arterial blood pressure in dialysis patients receiving maintenance erythropoietin therapy. J Am Soc Nephrol (1994) 4:1874–1878.[Abstract]
  30. Neusser M, Tepel M, Zidek W. Erythropoietin increases cytosolic free calcium concentration in vascular smooth muscle cells. Cardiovasc Res (1993) 27:1233–1236.[Abstract/Free Full Text]
  31. Takahashi K, Totsune K, Imai Y, et al. Plasma concentrations of immunoreactive-endothelin in patients with chronic renal failure treated with recombinant human erythropoietin. Clin Sci (1993) 84:47–50.[Web of Science][Medline]
  32. Bode-Böger SM, Böger RH, Kuhn M, et al. Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids. Kidney Int (1996) 50:1255–1261.[Web of Science][Medline]
  33. Carlini RG, Dusso AS, Obialo CI, et al. Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells. Kidney Int (1993) 43:1010–1014.[Web of Science][Medline]
  34. Eggena P, Willsey P, Jamgotchian N, et al. Influence of recombinant human erythropoietin on blood pressure and tissue renin-angiotensin systems. Am J Physiol (1991) 261:E642–E646.[Web of Science][Medline]
  35. Barrett JD, Zhang Z, Zhu JH, et al. Erythropoietin upregulates angiotensin receptors in cultured rat vascular smooth muscle cells. J Hypertens (1998) 16:1749–1757.[CrossRef][Web of Science][Medline]
  36. Kuriyama S, Tomonari H, Tokudome G, et al. Association of angiotensinogen gene polymorphism with erythropoietin-induced hypertension: a preliminary report. Hypertens Res (2001) 24:501–505.[CrossRef][Web of Science][Medline]
  37. Lebel M, Rodrigue ME, Agharazii M, et al. Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin. Am J Hypertens (2006) 19:1286–1292.[CrossRef][Web of Science][Medline]
  38. Rodrigue ME, Moreau C, Larivière R, et al. Relationship between eicosanoids and endothelin-1 in the pathogenesis of erythropoietin-induced hypertension in uremic rats. J Cardiovasc Pharmacol (2003) 41:388–395.[CrossRef][Web of Science][Medline]
  39. Rodrigue ME, Lacasse-M S, Larivière R, et al. Cyclooxygenase inhibition with acetylsalicylic acid unmasks a role for prostacyclin in erythropoietin-induced hypertension in uremic rats. Can J Physiol Pharmacol (2005) 83:467–475.[CrossRef][Web of Science][Medline]
  40. Anagnostou A, Lee ES, Kessimian N, et al. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA (1990) 87:5978–5982.[Abstract/Free Full Text]
  41. Ammarguellat F, Gogusev J, Drüeke TB. Direct effect of erythropoietin on rat vascular smooth-muscle cell via a putative erythropoietin receptor. Nephrol Dial Transplant (1996) 11:687–692.[Abstract/Free Full Text]
  42. Akimoto T, Kusano E, Ito C, et al. Involvement of erythropoietin-induced cytosolic free calcium mobilization in activation of mitogen-activated protein kinase and DNA synthesis in vascular smooth muscle cells. J Hypertens (2001) 19:193–202.[CrossRef][Web of Science][Medline]
  43. Carlini RG, Reyes AA, Rothstein M. Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int (1995) 47:740–745.[Web of Science][Medline]
  44. Satoh K, Kagaya Y, Nakano M, et al. Important role of endogenous erythropoietin system in recruitment of endothelial progenitor cells in hypoxia-induced pulmonary hypertension in mice. Circulation (2006) 113:1442–1450.[Abstract/Free Full Text]
  45. Yatsiv I, Grigoriadis N, Simeonidou C, et al. Erythropoietin is neuroprotective, improves functional recovery, and reduces neuronal apoptosis and inflammation in a rodent model of experimental closed head injury. FASEB J (2005) 19:1701–1703.[Abstract/Free Full Text]
  46. Van Der Meer P, Lipsic E, Henning RH, et al. Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia-reperfusion injury. Eur J Heart Fail (2004) 6:853–859.[Web of Science][Medline]
  47. Vaziri ND, Zhou XJ, Liao SY. Erythropoietin enhances recovery from cisplatin-induced acute renal failure. Am J Physiol (Renal Physiol) (1994) 266:F360–F366.[Abstract/Free Full Text]
  48. Kase S, Saito W, Ohgami K, et al. Expression of erythropoietin receptor in human epiretinal membrane of proliferative diabetic retinopathy. Br J Ophthalmol (2007) 91:1376–1378.[Abstract/Free Full Text]
  49. Nagarajan S, Mansfield E, Hsieh S, et al. Transplant reno-vascular stenoses associated with early erythropoietin use. Clin Transplant (2007) 21:597–608.[CrossRef][Web of Science][Medline]
  50. Bittorf T, Büchse T, Sasse T, et al. Activation of the transcription factor NF-kappaB by the erythropoietin receptor: structural requirements and biological significance. Cell Signal (2001) 13:673–681.[CrossRef][Web of Science][Medline]
  51. Chen HC, Tsai JC, Tsai JH, et al. Recombinant human erythropoietin enhances superoxide production by FMLP-stimulated polymorphonuclear leukocytes in hemodialysis patients. Kidney Int (1997) 52:1390–1394.[Web of Science][Medline]
  52. Kaupke CJ, Butler GC, Vaziri ND. Effect of recombinant human erythropoietin on platelet production in dialysis patients. J Am Soc Nephrol (1996) 3:1672–1679.
  53. Zhou XJ, Vaziri ND. Defective calcium signaling in uremic platelets and its amelioration with long-term erythropoietin therapy. Nephro Dial Transpl (2002) 17:992–997.[CrossRef]
  54. Kahraman S, Yilmaz R, Kirkpantur A, et al. Impact of rHuEPO therapy initiation on soluble adhesion molecule levels in haemodialysis patients. Nephrology (2005) 10:264–269.[CrossRef][Medline]
  55. Nagai T, Akizawa T, Kohjiro S, et al. rHuEPO enhances the production of plasminogen activator inhibitor-1 in cultured endothelial cells. Kidney Int (1996) 50:102–107.[Web of Science][Medline]
  56. Borawski J, Naumnik B, Mysliwiec M. Tissue factor and thrombomodulin in hemodialysis patients: associations with endothelial injury, liver disease, and erythropoietin therapy. Clin Appl Thromb Hemost (2002) 8:359–367.[Abstract/Free Full Text]
  57. Fusté B, Serradell M, Escolar G, et al. Erythropoietin triggers a signaling pathway in endothelial cells and increases the thrombogenicity of their extracellular matrices in vitro. Thromb Haemost (2002) 88:678–685.[Web of Science][Medline]
  58. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoeti administration for the treatment of cancer-associated anemia. JAMA (2008) 299:914–924.[Abstract/Free Full Text]
  59. Scalera F, Kielstein JT, Martens-Lobenhoffer J, et al. Erythropoietin increases asymmetric dimethylarginine in endothelial cells: role of dimethylarginine dimethylaminohydrolase. J Am Soc Nephrol (2005) 16:892–898.[Abstract/Free Full Text]
  60. Wang XQ, Vaziri ND. Erythropoietin depresses nitric oxide synthase expression by human endothelial cells. Hypertension (1999) 33:894–899.[Abstract/Free Full Text]
  61. Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol (1999) 10:1606–1615.[Free Full Text]
  62. McClellan WM, Flanders WD, Langston RD, et al. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol (2002) 13:1928–1936.[Abstract/Free Full Text]
  63. Astor BC, Arnett DK, Brown A, et al. Association of kidney function and hemoglobin with left ventricular morphology among African Americans: the Atherosclerosis Risk in Communities (ARIC) study. Am J Kidney Dis (2004) 43:836–835.[CrossRef][Web of Science][Medline]
  64. Silverberg DS, Wexler D, Blum M, et al. Aggressive therapy of congestive heart failure and associated chronic renal failure with medications and correction of anemia stops or slows the progression of both diseases. Perit Dial Int (2001) 3:S236–S240.
  65. Silverberg DS, Wexler D, Blum M, et al. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant (2003) 18:141–146.[Abstract/Free Full Text]
  66. Pascual J, Teruel JL, Moya JL, et al. Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: a prospective study. Clin Nephrol (1991) 35:280–287.[Web of Science][Medline]
  67. Portoles J, Torralbo A, Martin P, et al. Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis (1997) 29:541–548.[Web of Science][Medline]
  68. Hayashi T, Suzuki A, Shoji T, et al. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis (2000) 35:250–256.[Web of Science][Medline]
  69. Roger SD, McMahon LP, Clarkson A, et al. Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol (2004) 15:148–156.[Abstract/Free Full Text]
  70. Parfrey PS, Foley RN, Wittreich BH, et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol (2005) 16:2180–2189.[Abstract/Free Full Text]
  71. Levin A, Djurdjev O, Thompson C, et al. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis (2005) 46:799–811.[CrossRef][Web of Science][Medline]
  72. Ritz E, Laville M, Bilous RW, et al. Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) study. Am J Kidney Dis (2007) 49:194–207.[CrossRef][Web of Science][Medline]
  73. Van Der Meer P, Lipsic E, Henning RH, et al. Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia-reperfusion injury. Eur J Heart Fail (2004) 6:853–859.[Web of Science][Medline]
  74. Moon C, Krawczyk M, Ahn D, et al. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci USA (2003) 100:11612–11617.[Abstract/Free Full Text]
  75. Parsa CJ, Kim J, Riel RU, et al. Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts. J Biol Chem (2004) 279:20655–20662.[Abstract/Free Full Text]
  76. Parsa CJ, Matsumoto A, Kim J, et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest (2003) 112:999–1007.[CrossRef][Web of Science][Medline]
  77. Calvillo L, Latini R, Kajstura J, et al. Recombinant human erythropoietin protects the myocardium from ischemia reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA (2003) 100:4802–4806.[Abstract/Free Full Text]
  78. Westenfelder C, Biddle DL, Baranowski RL. Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int (1999) 55:808–820.[CrossRef][Web of Science][Medline]
  79. Abdelrahman M, Sharples EJ, McDonald MC, et al. Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock (2004) 22:63–69.[CrossRef][Web of Science][Medline]
  80. Vesey DA, Cheung C, Pat B, et al. Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant (2004) 19:348–355.[Abstract/Free Full Text]
  81. Spandou E, Tsouchnikas I, Karkavelas G, et al. Erythropoietin attenuates renal injury in experimental acute renal failure ischaemic/reperfusion model. Nephrol Dial Transplant (2006) 21:330–336.[Abstract/Free Full Text]
  82. Logar CM, Brinkkoetter PT, Krofft RD, et al. Darbepoetin alfa protects podocytes from apoptosis in vitro and in vivo. Kidney Int (2007) 72:489–498.[CrossRef][Web of Science][Medline]
  83. Bahlmann FH, Song R, Boehm SM, et al. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation (2004) 100:1006–1012.
  84. Menne J, Park JK, Shushakova N, et al. Continuous erythropoietin receptor activation affects different pathways of diabetic renal injury. J Am Soc Nephrol (2007) 18:2046–2053.[Abstract/Free Full Text]
  85. Gouva C, Nikolopoulos P, Ioannidis JP, et al. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int (2004) 66:753–760.[CrossRef][Web of Science][Medline]
  86. Garcia DL, Anderson S, Rennke HG, et al. Anemia lessens and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass. Proc Natl Acad Sci USA (1988) 85:6142–6146.[Abstract/Free Full Text]
  87. Tong Z, Yang Z, Patel S, et al. Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. Proc Natl Acad Sci USA (2008) 105:6998–7003.[Abstract/Free Full Text]
Received for publication: 13. 6.08
Accepted in revised form: 1.10.08


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
24/4/1082    most recent
gfn601v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Vaziri, N. D.
Right arrow Articles by Zhou, X. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vaziri, N. D.
Right arrow Articles by Zhou, X. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?